Immutep (ASX:IMM) intends to focus future eftilagimod alfa development on two cancer settings after TACTI-004 stopped early for futility. Its continuing review has identified differences between product made at two Manufacturing scales, but has not established a definitive cause of the trial outcome.

A LAG-3 Fusion Protein Designed to Activate the Immune System

Eftilagimod alfa, known as efti, is Immutep's lead product candidate, a soluble LAG-3 fusion protein designed to activate antigen-presenting cells and broadly stimulate the immune system's response against tumours. Unlike checkpoint inhibitors that block a single suppressive signal, efti is designed to work upstream, priming a wider immune response that the company has explored in combination with existing chemotherapy and immunotherapy regimens across several tumour types.

Refocusing on HNSCC and Soft Tissue Sarcoma

In September 2026, Immutep outlined a focused development strategy concentrating on head and neck squamous cell carcinoma in patients with low PD-L1 expression, where efti has Fast Track Designation and has had constructive engagement with the US FDA, and on soft tissue sarcoma in the neoadjuvant setting, following positive Phase II data and an Orphan Drug Designation granted in April 2026. A pooled analysis of five efti trials presented at the 2026 ASCO meeting showed a 7.7-month median overall survival benefit among biological responders, underpinning the company's confidence in these two indications specifically.

A Manufacturing Issue, and How the Company Is Addressing It

Immutep identified subtle structural and analytical differences, including N-glycan structure, between efti made at 2,000-litre scale for TACTI-004 and batches made at 200-litre scale for earlier studies. The company considers the differences potentially relevant and has contracted a new 200-litre manufacturing run. Its root-cause analysis remains ongoing. A start for further trials is targeted for the second half of 2027, subject to trial design, regulatory discussions, manufacturing, partners and resources.

Why the Refocus Matters for Immutep's Positioning

Immuno-oncology remains one of the most closely watched sub-sectors on the ASX healthcare boards, and companies with a differentiated mechanism of action — as opposed to another checkpoint inhibitor — tend to attract disproportionate attention from both specialist investors and potential pharmaceutical partners. By narrowing efti's focus to the two indications with the clearest supporting data, Immutep is signalling Capital discipline to a sector where investors have grown wary of biotechnology companies spreading limited resources across too many indications at once.

What This Means, and the Risks Ahead

The manufacturing differences remain a line of investigation. TACTI-004 was stopped after an interim futility analysis, while proposed studies remain subject to preparatory work. The completed review, clinical designs and manufacturing validation will inform future development decisions.